

CITATION REPORT

List of articles citing

Overall cardiovascular profile of sildenafil citrate

DOI: 10.1016/s0002-9149(99)00046-6

American Journal of Cardiology, 1999, 83, 35C-44C.

Source: <https://exaly.com/paper-pdf/30566183/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|-----|---|-----|-----------|
| 263 | Medical treatment of erectile dysfunction. 1999 , 31, 388-98 | | 24 |
| 262 | Sildenafil (Viagra) and ophthalmology. <i>Survey of Ophthalmology</i> , 1999 , 44, 153-62 | 6.1 | 136 |
| 261 | Viagra and Cardiovascular Disease. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 1999 , 4, 259-267 | 2.6 | 12 |
| 260 | Sildenafil: a review of its use in erectile dysfunction. 1999 , 57, 967-89 | | 138 |
| 259 | The epidemiology, anatomy, physiology, and treatment of erectile dysfunction in chronic renal failure patients. 1999 , 6, 296-309 | | 14 |
| 258 | Safety of sildenafil. 2000 , 10, 613-5 | | 2 |
| 257 | Effect of sildenafil citrate on blood pressure and heart rate in men with erectile dysfunction taking concomitant antihypertensive medication. Sildenafil Study Group. 2000 , 18, 1865-9 | | 77 |
| 256 | Diltiazem-mediated inhibition of sildenafil metabolism may promote nitrate-induced hypotension. 2000 , 30, 641-2 | | 12 |
| 255 | Sexual intercourse and stable angina pectoris. <i>American Journal of Cardiology</i> , 2000 , 86, 35F-37F | 3 | 26 |
| 254 | Cardiovascular risk and sildenafil. <i>American Journal of Cardiology</i> , 2000 , 86, 57F-61F | 3 | 65 |
| 253 | Importance of asking questions about erectile dysfunction. <i>American Journal of Cardiology</i> , 2000 , 86, 1210-3, A5 | 3 | 32 |
| 252 | Effect of sildenafil on coronary active and reactive hyperemia. 2000 , 279, H2319-25 | | 21 |
| 251 | Progress in Erectile Dysfunction and Hormone Function. 2000 , 3, 169-175 | | |
| 250 | Hemodynamic effects of sildenafil in men with severe coronary artery disease. 2000 , 342, 1622-6 | | 257 |
| 249 | Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. 2000 , 102, 275-7 | | 85 |
| 248 | Effects of sildenafil citrate (Viagra) combined with nitrate on the heart. 2000 , 102, 2516-21 | | 77 |
| 247 | Teaching professionalism to medical students. 2000 , 283, 197-8 | | 2 |

| | | |
|-----|--|--------|
| 246 | Sex and the patient with cardiovascular risk factors: focus on sildenafil. 2000 , 109 Suppl 9A, 13S-21S; discussion 29S-30S | 32 |
| 245 | Cardiovascular effects of oral pharmacotherapy in erectile dysfunction. 2000 , 16 Suppl 1, s42-7 | |
| 244 | Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. 2000 , 36, 25-31 | 146 |
| 243 | Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. 2000 , 36, 845-51 | 250 |
| 242 | A risk-benefit assessment of sildenafil in the treatment of erectile dysfunction. 2001 , 24, 255-65 | 3 |
| 241 | Leptin in nonalcoholic steatohepatitis: is it one of the bits? 2001 , 96, 2519-2520 | 2 |
| 240 | Sildenafil citrate (Viagra) does not exacerbate myocardial ischemia in canine models of coronary artery stenosis. 2001 , 37, 286-92 | 39 |
| 239 | Efectividad del tratamiento con sildenafilo en pacientes con disfunci3n er3ctil e hipertensi3n arterial. 2001 , 18, 65-71 | |
| 238 | Sildenafil citrate: a therapeutic update. 2001 , 23, 2-23 | 65 |
| 237 | Oral drug therapy for erectile dysfunction. 2001 , 28, 321-34 | 71 |
| 236 | DIRECT EFFECTS OF SELECTIVE TYPE 5 PHOSPHODIESTERASE INHIBITORS ALONE OR WITH OTHER VASODILATORS ON THE ERECTILE RESPONSE IN CATS. <i>Journal of Urology</i> , 2001 , 165, 1004-1009 ^{2.5} | 11 |
| 235 | [Results after treatment with sildenafil citrate in 100 patients with erectile dysfunction]. 2001 , 25, 335-40 | |
| 234 | Sildenafil overdose in a female patient. 2001 , 39, 423-4 | 5 |
| 233 | Potential of sildenafil-induced hypotension is minimal with nitrates generating a radical intermediate. <i>Journal of Cardiovascular Pharmacology</i> , 2001 , 38, 149-55 | 3.1 13 |
| 232 | Drugs acting on the cerebral and peripheral circulations. 2001 , 229-232 | |
| 231 | Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. 2001 , 103, E119-20; author reply E119-20 | 2 |
| 230 | Sildenafil citrate, a selective phosphodiesterase type 5 inhibitor: urologic and cardiovascular implications. 2001 , 19, 40-5 | 15 |
| 229 | Aphrodisiacs past and present: a historical review. 2001 , 11, 303-7 | 97 |

| | | | |
|-----|---|-----|-----|
| 228 | Diltiazem-mediated inhibition of sildenafil metabolism may promote nitrate-induced hypotension. 2001 , 31, 373; author reply 374-5 | | 3 |
| 227 | The role of apomorphine SL in the treatment of male erectile dysfunction. 2001 , 88 Suppl 3, 36-8 | | 10 |
| 226 | Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum. 2001 , 268, 3304-12 | | 72 |
| 225 | The cardiovascular response to sexual activity: do we know enough?. 2001 , 24, 271-5 | | 13 |
| 224 | Sexual function in spinal cord lesioned men. 2001 , 39, 455-70 | | 120 |
| 223 | Sexuality in the older person. 2001 , 30, 121-4 | | 49 |
| 222 | Cardiac electrophysiologic and hemodynamic effects of sildenafil, a PDE5 inhibitor, in anesthetized dogs. <i>Journal of Cardiovascular Pharmacology</i> , 2001 , 38, 940-6 | 3.1 | 30 |
| 221 | Anterior ischemic optic neuropathy associated with viagra. 2001 , 21, 22-5 | | 82 |
| 220 | Leptin in nonalcoholic steatohepatitis: is it one of the "hits"?. 2001 , 96, 2519-20 | | 3 |
| 219 | Hemorrhoidal bleeding associated with sildenafil. 2001 , 96, 2518-9 | | 13 |
| 218 | Male sexual function and its disorders: physiology, pathophysiology, clinical investigation, and treatment. 2001 , 22, 342-88 | | 164 |
| 217 | Regression of Apo B deficiency in biovular twins with Apo B deficiency and celiac disease after gluten withdrawal. 2002 , 97, 1856-8 | | |
| 216 | Sildenafil (viagra) is a risk factor for acute variceal bleeding. 2002 , 97, 1856 | | 38 |
| 215 | Caroli's syndrome in two siblings. 2002 , 97, 1855-6 | | 2 |
| 214 | Interaction of sildenafil with cAMP-mediated vasodilation in vivo. 2002 , 40, 763-7 | | 24 |
| 213 | Intracavernous injections for erectile dysfunction in patients with cardiovascular diseases and failure or contraindications for sildenafil citrate. 2002 , 14, 38-43 | | 34 |
| 212 | Safe sex for men with coronary artery disease: exercise, sildenafil, and risk of cardiac events. 2002 , 287, 766-7 | | 8 |
| 211 | Reimbursement claims analysis of outcomes with carvedilol and metoprolol. 2002 , 36, 386-91 | | 5 |

| | | |
|-----|--|-----|
| 210 | Pharmacological aspects of erectile dysfunction. 2002 , 89, 101-12 | 14 |
| 209 | Sildenafil (Viagra) augments sodium nitroprusside-induced but not nitroglycerin-induced hypotension in dogs. 2002 , 94, 1505-9, table of contents | 1 |
| 208 | Sildenafil (Viagrafi) Augments Sodium Nitroprusside-Induced But Not Nitroglycerin-Induced Hypotension in Dogs. 2002 , 94, 1505-1509 | 9 |
| 207 | Effects of sildenafil citrate (Viagra) on choroidal congestion. 2002 , 216, 455-8 | 37 |
| 206 | Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. 2002 , 90, 21-8 | 375 |
| 205 | Caroli's syndrome in two siblings. 2002 , 97, 1855-1856 | 1 |
| 204 | Effects of sildenafil citrate (viagra) on blood pressure in normotensive and hypertensive men. 2002 , 59, 747-52 | 58 |
| 203 | Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction. 2002 , 60, 4-11 | 117 |
| 202 | Summary of information on human CYP enzymes: human P450 metabolism data. 2002 , 34, 83-448 | 663 |
| 201 | The Role of Apomorphine SL in the Treatment of Erectile Dysfunction. 2002 , 1, 4-11 | 4 |
| 200 | Effects of sildenafil citrate (viagra) on cardiac repolarization and on autonomic control in subjects with chronic heart failure. 2002 , 143, 703-10 | 45 |
| 199 | To the Editor of Nature Reviews Drug Discovery. 2002 , 1, 740-740 | |
| 198 | Interactions of sildenafil with various coronary vasodilators in isolated porcine coronary artery. 2002 , 437, 155-63 | 17 |
| 197 | The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers. 2002 , 53 Suppl 1, 37S-43S | 39 |
| 196 | Onset and duration of action of sildenafil for the treatment of erectile dysfunction. 2002 , 53 Suppl 1, 61S-65S | 68 |
| 195 | Insulin resistance, a new target for nitric oxide-delivery drugs. 2002 , 16, 441-53 | 35 |
| 194 | Clinical efficacy and safety of sildenafil citrate (Viagra) in a multi-racial population in Singapore: A retrospective study of 1520 patients. 2002 , 9, 308-15 | 16 |
| 193 | Interactions between drugs for erectile dysfunction and drugs for cardiovascular disease. 2002 , 14, 178-88 | 25 |

| | | | |
|-----|---|-----|-----|
| 192 | The effect of sildenafil on electrostimulation-induced erection in the rat model. 2002 , 14, 251-5 | | 11 |
| 191 | Tolerability and safety profile of sildenafil citrate (Viagra) in Latin American patient populations. 2002 , 14 Suppl 2, S54-9 | | 8 |
| 190 | The clinical safety of viagra. 2002 , 962, 378-88 | | 33 |
| 189 | Potential for use of pulse wave analysis in determining the interaction between sildenafil and glyceryl trinitrate. 2002 , 25, 295-9 | | 19 |
| 188 | Erectile dysfunction in the cardiac patient. 2003 , 4, 466-71 | | 16 |
| 187 | Effects of sildenafil citrate (Viagra) on hemodynamic parameters during exercise testing and occurrence of ventricular arrhythmias in patients with erectile dysfunction and cardiovascular disease. 2003 , 43, 544-51 | | 12 |
| 186 | Sildenafil in patients with cardiovascular disease. <i>American Journal of Cardiology</i> , 2003 , 92, 26M-36M | 3 | 32 |
| 185 | Cardiovascular effects of tadalafil. <i>American Journal of Cardiology</i> , 2003 , 92, 37M-46M | 3 | 98 |
| 184 | Overview of phosphodiesterase 5 inhibition in erectile dysfunction. <i>American Journal of Cardiology</i> , 2003 , 92, 9M-18M | 3 | 160 |
| 183 | Potential role of type 5 phosphodiesterase inhibition in the treatment of congestive heart failure. 2003 , 9, 9-15 | | 27 |
| 182 | Efficacy and safety of sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men in Egypt and South Africa. 2003 , 15 Suppl 1, S25-9 | | 20 |
| 181 | Early experience with sildenafil for the treatment of erectile dysfunction in renal transplant recipients. 2003 , 18, 411-7 | | 28 |
| 180 | Nitric oxide-releasing drugs. 2003 , 43, 97-123 | | 178 |
| 179 | Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. 2003 , 108, 239-44 | | 124 |
| 178 | Sildenafil in erectile dysfunction: a critical review. 2003 , 19, 241-62 | | 77 |
| 177 | An update on the PDE-5 inhibitors (PDE-5i). 2003 , 24, S52-8 | | 17 |
| 176 | Hepatic sinusoidal-obstruction syndrome: toxicity of pyrrolizidine alkaloids. 2003 , 39, 437-46 | | 105 |
| 175 | Current and future trends in the oral pharmacotherapy of male erectile dysfunction. <i>Expert Opinion on Investigational Drugs</i> , 2003 , 12, 1521-33 | 5.9 | 10 |

| | | | |
|-----|---|-----|----|
| 174 | Sildenafil citrate does not affect cardiac contractility in human or dog heart. 2003 , 19, 747-52 | | 59 |
| 173 | Effect of sildenafil on arterial stiffness and wave reflection. 2003 , 8, 243-8 | | 67 |
| 172 | Effects of sildenafil (viagra) on human myocardial contractility, in vitro arrhythmias, and tension of internal mammaria arteries and saphenous veins. <i>Journal of Cardiovascular Pharmacology</i> , 2003 , 41, 734-43 | | 42 |
| 171 | Erectile dysfunctions. 2003 , 2, 350-6 | | 2 |
| 170 | Pharmacologic update: treatment of erectile dysfunction in the elderly with phosphodiesterase type 5 inhibitors: cardiovascular implications. 2004 , 13, 332-5 | | |
| 169 | Advances in the Treatment of Erectile Dysfunction: A Focus on Tadalafil. 2004 , 17, 239-250 | | 1 |
| 168 | Rechallenge prior sildenafil nonresponders. 2004 , 16, 64-8 | | 30 |
| 167 | Preclinical safety profile of sildenafil. 2004 , 16, 498-504 | | 35 |
| 166 | Nitric oxide-cyclic GMP pathway with some emphasis on cavernosal contractility. 2004 , 16, 459-69 | | 54 |
| 165 | Haemodynamic effects of the selective phosphodiesterase 5 inhibitor, UK-357,903, in conscious SHR. 2004 , 141, 114-22 | | 5 |
| 164 | Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events. <i>Journal of Sexual Medicine</i> , 2004 , 1, 161-7 | 1.1 | 38 |
| 163 | Treatment program for erectile dysfunction in patients with cardiovascular diseases. <i>American Journal of Cardiology</i> , 2004 , 93, 689-93 | 3 | 11 |
| 162 | Effects of a phosphodiesterase-5 (PDE5) inhibitor on endothelium-dependent relaxation of myometrial small arteries. 2004 , 190, 1283-90 | | 51 |
| 161 | Novel phosphodiesterase type 5 inhibitors: assessing hemodynamic effects and safety parameters. 2004 , 27, 120-5 | | 22 |
| 160 | Erectile dysfunction in the cardiac patient. 2004 , 30, 50-4 | | 6 |
| 159 | No adverse hemodynamic interaction between sildenafil and red wine. 2004 , 76, 365-70 | | 8 |
| 158 | Erectile dysfunction and cardiovascular disease. 2004 , 79, 782-94 | | 14 |
| 157 | New treatment options for erectile dysfunction in patients with diabetes mellitus. 2004 , 64, 2667-88 | | 69 |

| | | | |
|-----|--|---|-----|
| 156 | The discovery and development of Viagrafi (sildenafil citrate). 2004 , 1-13 | | 4 |
| 155 | Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. 2004 , 64, 998-1003; discussion 1003-4 | | 54 |
| 154 | Erectile dysfunction in essential arterial hypertension and effects of sildenafil: results of a Spanish national study. 2004 , 17, 139-45 | | 52 |
| 153 | Sildenafil: emerging cardiovascular indications. 2004 , 78, 1496-506 | | 53 |
| 152 | Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. 2004 , 110, 3149-55 | | 143 |
| 151 | Recreational use of sildenafil by HIV-positive and -negative homosexual/bisexual males. 2004 , 38, 1024-30 | | 49 |
| 150 | Erectile Dysfunction and Cardiovascular Disease. 2004 , 79, 782-794 | | 49 |
| 149 | Autonomic dysreflexia during sperm retrieval in spinal cord injury: influence of lesion level and sildenafil citrate. 2005 , 99, 53-8 | | 74 |
| 148 | Erectile dysfunction drugs and non-arteritic anterior ischemic optic neuropathy: is there a cause and effect relationship?. 2005 , 25, 295-8 | | 47 |
| 147 | Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system. 2005 , 95 Suppl 4, 19-28 | | 39 |
| 146 | The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease. 2005 , 60, 459-68 | | 19 |
| 145 | A case of erectile dysfunction and risk factors for coronary artery disease. 2005 , 17 Suppl 1, S7-S11 | | 3 |
| 144 | Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). <i>American Journal of Cardiology</i> , 2005 , 96, 313-21 | 3 | 216 |
| 143 | Cardiac safety in clinical trials of phosphodiesterase 5 inhibitors. <i>American Journal of Cardiology</i> , 2005 , 96, 37M-41M | 3 | 36 |
| 142 | Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). <i>American Journal of Cardiology</i> , 2005 , 96, 85M-93M | 3 | 99 |
| 141 | The therapeutic dilemma: how to use short-acting PDE5 inhibitor drugs. 2005 , 28 Suppl 2, 69-73 | | 2 |
| 140 | [Benefits and risks of nitrate preparations in the treatment of angina pectoris]. 2005 , 46, 713-4 | | |
| 139 | Therapie der erektilen Dysfunktion. 2005 , 341-352 | | |

| | | | |
|-----|--|-----|-----|
| 138 | Efficacy, safety and tolerability of sildenafil in Brazilian hypertensive patients on multiple antihypertensive drugs. 2005 , 31, 342-53; discussion 354-5 | | 10 |
| 137 | Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction. 2005 , 2, 239-47 | | 40 |
| 136 | Sildenafil: efficacy, safety, tolerability and mechanism of action in treating erectile dysfunction. 2005 , 1, 283-93 | | 34 |
| 135 | Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension. 2005 , 171, 275-81 | | 193 |
| 134 | Erectile dysfunction and subsequent cardiovascular disease. 2005 , 294, 2996-3002 | | 625 |
| 133 | Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. 2005 , 172, 105-13 | | 266 |
| 132 | Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction. 2005 , 32, 419-29, vi | | 34 |
| 131 | Oral Pharmacotherapy for Male Sexual Dysfunction. 2005 , | | |
| 130 | Sildenafil Does Not Alter Retrobulbar Hemodynamics in Postural Variations. 2005 , 29, 59-64 | | 7 |
| 129 | Effects of combined treatment with sildenafil and itraconazole on the cardiovascular system in telemetered conscious dogs. 2005 , 28, 177-86 | | 3 |
| 128 | Strategies in the oral pharmacotherapy of male erectile dysfunction viewed from bench and bedside (Part I). 2005 , 2, 87-94 | | 2 |
| 127 | Treatment of pulmonary arterial hypertension with sildenafil: from pathophysiology to clinical evidence. 2006 , 20, 722-35 | | 22 |
| 126 | The effects of tamsulosin and sildenafil in separate and combined regimens on detailed hemodynamics in patients with benign prostatic enlargement. <i>Journal of Urology</i> , 2006 , 176, 2551-6 | 2.5 | 14 |
| 125 | Hypotensive potential of sildenafil and tamsulosin during orthostasis. 2006 , 26, 667-71 | | 6 |
| 124 | Effect of regular phosphodiesterase type 5 inhibition in hypertension. 2006 , 48, 622-7 | | 80 |
| 123 | Cardiovascular safety of sildenafil citrate (Viagra): an updated perspective. 2006 , 68, 47-60 | | 55 |
| 122 | Guidelines for the prevention, detection and management of people with chronic heart failure in Australia 2006. 2006 , 185, 549-57 | | 100 |
| 121 | Sildenafil-associated coronary thrombosis in a patient with angiographically normal coronary arteries: a case report with review of literature. 2006 , 13, 378-84 | | 3 |

| | | |
|-----|---|-----|
| 120 | Effects of sildenafil citrate on defibrillation efficacy. 2006 , 17, 292-5 | 14 |
| 119 | Effect of vardenafil, an inhibitor of phosphodiesterase-5, on portal haemodynamics in normal and cirrhotic liver -- results of a pilot study. 2006 , 23, 121-8 | 50 |
| 118 | Vasodilatory and hypoglycaemic effects of two pyrano-isoflavone extractives from <i>Eriosema kraussianum</i> N. E. Br. [Fabaceae] rootstock in experimental rat models. 2006 , 67, 610-7 | 26 |
| 117 | The effect of ciprofloxacin and clarithromycin on sildenafil oral bioavailability in human volunteers. 2006 , 27, 103-10 | 26 |
| 116 | Effect of intravenous sildenafil on pulmonary hemodynamics and gas exchange in the presence and absence of acute lung injury in piglets. 2006 , 59, 762-6 | 13 |
| 115 | Cardiovascular effects of phosphodiesterase 5 inhibitors. <i>Current Pharmaceutical Design</i> , 2006 , 12, 3485-94 | 45 |
| 114 | Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. 2007 , 115, 59-66 | 285 |
| 113 | Erectile dysfunction and hypertension. 2007 , 19, 296-302 | 67 |
| 112 | Effects of vardenafil on intraocular pressure and orbital hemodynamics. 2007 , 23, 275-9 | 4 |
| 111 | Hypertrophied right hearts get two for the price of one: can inhibiting phosphodiesterase type 5 also inhibit phosphodiesterase type 3?. 2007 , 116, 233-5 | 5 |
| 110 | Sildenafil citrate (Viagra) enhances vasodilatation by atrial natriuretic peptide in normal dogs. 2007 , 71, 1965-9 | 4 |
| 109 | Cyclic guanosine monophosphate phosphodiesterase-5 inhibitor promotes an endothelium NO-dependent-like vasodilation in patients with refractory hypertension. 2007 , 16, 315-21 | 11 |
| 108 | Sildenafil therapy for pulmonary arterial hypertension associated with atrial septal defects. 2007 , 118, 178-82 | 31 |
| 107 | Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus. 2007 , CD002187 | 50 |
| 106 | Pulmonary hypertension in older adults. 2007 , 28, 717-33, vi | 11 |
| 105 | Treatment options for erectile dysfunction. 2007 , 36, 465-79 | 32 |
| 104 | Anterior ischemic optic neuropathy and stroke with use of PDE-5 inhibitors for erectile dysfunction: cause or coincidence?. 2007 , 262, 89-97 | 26 |
| 103 | Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors. 2007 , 61, 1547-54 | 20 |

| | | | |
|-----|---|-----|----|
| 102 | Effect of sildenafil citrate (Viagra) on coronary flow in normal subjects. 2008 , 25, 72-6 | | 3 |
| 101 | Blood pressure control and sildenafil--carrot stick or sword of Damocles?. <i>American Journal of Cardiology</i> , 2007 , 100, 552-3 | 3 | 2 |
| 100 | Hypoglycaemic effect of <i>Eriosema kraussianum</i> N. E. Br. [Fabaceae] rootstock hydro-alcohol extract in rats. 2007 , 61, 244-250 | | 4 |
| 99 | Pulmonary embolism after tadalafil ingestion. 2008 , 30, 610-2 | | 6 |
| 98 | Phosphodiesterase 5 inhibition in essential hypertension. 2008 , 10, 52-7 | | 27 |
| 97 | Influence of sildenafil on lung diffusion during exposure to acute hypoxia at rest and during exercise in healthy humans. 2008 , 103, 421-30 | | 29 |
| 96 | Bilateral cerebral hemispheric infarction associated with sildenafil citrate (Viagra) use. 2008 , 15, 306-8 | | 12 |
| 95 | Expression, activity, and pro-hypertrophic effects of PDE5A in cardiac myocytes. 2008 , 20, 2231-6 | | 74 |
| 94 | An open-label, multicenter, flexible dose study to evaluate the efficacy and safety of Viagra (sildenafil citrate) in Korean men with erectile dysfunction and arterial hypertension who are taking antihypertensive agents. <i>Journal of Sexual Medicine</i> , 2008 , 5, 2405-13 | 1.1 | 5 |
| 93 | The GAF domain of the cGMP-binding, cGMP-specific phosphodiesterase (PDE5) is a sensor and a sink for cGMP. 2008 , 47, 3534-43 | | 37 |
| 92 | Pharmacokinetics and safety of ambrisentan in combination with sildenafil in healthy volunteers. 2008 , 48, 1451-9 | | 59 |
| 91 | Non-arteritic anterior ischaemic optic neuropathy and phosphodiesterase-5 inhibitors. 2008 , 92, 1577-80 | | 28 |
| 90 | Sildenafil acts on the central nervous system increasing sympathetic activity. 2008 , 104, 1683-9 | | 25 |
| 89 | Role of sildenafil in neurological disorders. 2008 , 31, 353-62 | | 36 |
| 88 | Phosphodiesterase inhibitors and the eye. 2009 , 37, 514-23 | | 34 |
| 87 | A fatal hypotension by sildenafil in an end-stage renal disease patient with hypertension and abnormal pharmacokinetics of the medicine. 2009 , 14, 357-8 | | 4 |
| 86 | Nonarteritic ischaemic optic neuropathy (NAION) after 36 h of intake of sildenafil citrate: first Egyptian case. 2009 , 41, 319-21 | | 11 |
| 85 | Chronic inhibition of nitric-oxide synthase induces hypertension and erectile dysfunction in the rat that is not reversed by sildenafil. 2010 , 106, 78-83 | | 27 |

| | | | |
|----|--|-----|-----|
| 84 | Managing Erectile Dysfunction in Patients With Cardiovascular Diseases: The Efficacy and Safety of Phosphodiesterase-5 Inhibitors. 2009 , 3, 201-211 | | 1 |
| 83 | Urogenital dysfunction in patients with multiple sclerosis. 2009 , 21 Suppl 2, 22-7 | | |
| 82 | Phosphodiesterase 5 inhibitors: are they cardioprotective?. 2009 , 83, 204-12 | | 29 |
| 81 | Acute pulmonary hypertension in infants and children: cGMP-related drugs. 2010 , 11, S37-40 | | 9 |
| 80 | Pharmacotherapy for erectile dysfunction. <i>Journal of Sexual Medicine</i> , 2010 , 7, 524-40 | 1.1 | 132 |
| 79 | Effect of sildenafil on neuropathic pain and hemodynamics in rats. 2010 , 51, 82-7 | | 16 |
| 78 | Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension. 2010 , 122, 88-95 | | 78 |
| 77 | The effect of sildenafil citrate administration on selected physiological parameters of exercising Thoroughbred horses. 2010 , 42, 606-12 | | 6 |
| 76 | Comprehensive Cardiovascular Medicine in the Primary Care Setting. 2011 , | | |
| 75 | Not just for men. <i>Survey of Ophthalmology</i> , 2011 , 56, 173-7 | 6.1 | 8 |
| 74 | A phase III, multicenter, collaborative, open-label clinical trial of sildenafil in Japanese patients with pulmonary arterial hypertension. 2011 , 75, 677-82 | | 17 |
| 73 | Are phosphodiesterase type 5 inhibitors associated with vision-threatening adverse events? A critical analysis and review of the literature. <i>Journal of Sexual Medicine</i> , 2011 , 8, 2894-903 | 1.1 | 55 |
| 72 | Erectile dysfunction and cardiovascular disease. 2011 , 123, 7-16 | | 11 |
| 71 | Bilateral simultaneous anterior ischemic optic neuropathy associated with sildenafil. 2011 , 2, 262-5 | | 16 |
| 70 | Management of sexual dysfunction in Parkinson's disease. 2011 , 4, 375-83 | | 77 |
| 69 | Erectile dysfunction and hypertension: impact on cardiovascular risk and treatment. 2012 , 2012, 627278 | | 44 |
| 68 | Erectile dysfunction is not independently associated with cardiovascular death: data from the vitamins and lifestyle (VITAL) study. <i>Journal of Sexual Medicine</i> , 2012 , 9, 2104-10 | 1.1 | 21 |
| 67 | Anterior ischemic optic neuropathy associated with udenafil. 2012 , 26, 235-8 | | 5 |

| | | | |
|----|--|-----|----|
| 66 | Quantitative analysis of sildenafil and tadalafil in various fake drugs recently distributed in Korea. 2012 , 57, 1637-40 | | 19 |
| 65 | Drug-induced thrombosis: an update. 2013 , 36, 585-603 | | 36 |
| 64 | Herpes simplex virus infection and erectile dysfunction: a nationwide population-based study. 2013 , 1, 240-4 | | 6 |
| 63 | Effect of sildenafil citrate on the structure of rat liver. <i>Egyptian Journal of Histology</i> , 2013 , 36, 991-1003 | 0.8 | |
| 62 | Sildenafil citrate protects skeletal muscle of ischemia-reperfusion injury: immunohistochemical study in rat model. <i>Acta Cirurgica Brasileira</i> , 2013 , 28, 282-7 | 1.6 | 14 |
| 61 | Sexual Dysfunction in Patients with Neurologic Disorders. 2014 , 633-656 | | 1 |
| 60 | Regulation of OSU-03012 toxicity by ER stress proteins and ER stress-inducing drugs. <i>Molecular Cancer Therapeutics</i> , 2014 , 13, 2384-98 | 6.1 | 37 |
| 59 | GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial Diseases. <i>Journal of Cellular Physiology</i> , 2015 , 230, 2552-78 | 7 | 41 |
| 58 | GRP78/BiP/HSPA5/Dna K is a universal therapeutic target for human disease. <i>Journal of Cellular Physiology</i> , 2015 , 230, 1661-76 | 7 | 63 |
| 57 | OSU-03012 and Viagra Treatment Inhibits the Activity of Multiple Chaperone Proteins and Disrupts the Blood-Brain Barrier: Implications for Anti-Cancer Therapies. <i>Journal of Cellular Physiology</i> , 2015 , 230, 1982-98 | 7 | 34 |
| 56 | Penile histomorphometrical evaluation in hypertensive rats treated with sildenafil or enalapril alone or in combination: a comparison with normotensive and untreated hypertensive rats. <i>Journal of Sexual Medicine</i> , 2015 , 12, 39-47 | 1.1 | 11 |
| 55 | Effects of Nigella sativa, Lepidium sativum and Trigonella foenum-graecum on sildenafil disposition in beagle dogs. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2015 , 40, 219-24 | 2.7 | 10 |
| 54 | Sexual Dysfunction in Men and Women. 2016 , 785-830 | | 1 |
| 53 | Cardiac safety profile of sildenafil: chronotropic, inotropic and coronary vasodilator effects in the canine isolated, blood-perfused heart preparations. <i>Journal of Toxicological Sciences</i> , 2016 , 41, 739-744 | 1.9 | 1 |
| 52 | A Phase I proof-of-concept and safety trial of sildenafil to treat cerebral vasospasm following subarachnoid hemorrhage. <i>Journal of Neurosurgery</i> , 2016 , 124, 318-27 | 3.2 | 12 |
| 51 | Antihypertensive Drugs and Male Sexual Dysfunction: A Review of Adult Hypertension Guideline Recommendations. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2016 , 21, 233-44 | 2.6 | 24 |
| 50 | Stability of sildenafil in combination with heparin and dopamine. <i>American Journal of Health-System Pharmacy</i> , 2017 , 74, e64-e71 | 2.2 | |
| 49 | From Age-Related Cognitive Decline to Alzheimer's Disease: A Translational Overview of the Potential Role for Phosphodiesterases. <i>Advances in Neurobiology</i> , 2017 , 17, 135-168 | 2.1 | 17 |

| | | | |
|----|--|-----|-----|
| 48 | Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease. <i>Expert Opinion on Investigational Drugs</i> , 2017 , 26, 1033-1048 | 5.9 | 90 |
| 47 | Phosphodiesterase inhibition and modulation of corticostriatal and hippocampal circuits: Clinical overview and translational considerations. <i>Neuroscience and Biobehavioral Reviews</i> , 2018 , 87, 233-254 | 9 | 36 |
| 46 | Intersection of Pulmonary Hypertension and Right Ventricular Dysfunction in Patients on Left Ventricular Assist Device Support: Is There a Role for Pulmonary Vasodilators?. <i>Circulation: Heart Failure</i> , 2018 , 11, e004255 | 7.6 | 17 |
| 45 | A New Perspective on the Nitrate-Phosphodiesterase Type 5 Inhibitor Interaction. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018 , 23, 375-386 | 2.6 | 9 |
| 44 | Erectile Dysfunction. <i>Contemporary Cardiology</i> , 2019 , 379-387 | 0.1 | |
| 43 | The Serendipitous Story of Sildenafil: An Unexpected Oral Therapy for Erectile Dysfunction. <i>Sexual Medicine Reviews</i> , 2019 , 7, 115-128 | 5.6 | 53 |
| 42 | Subarachnoid haemorrhage following first use of Sildenafil. <i>Journal of Clinical Urology</i> , 2019 , 12, 322-323 | 0.2 | 0 |
| 41 | Effects of phosphodiesterase type 5 inhibitors on choroid and ocular vasculature: a literature review. <i>International Journal of Retina and Vitreous</i> , 2020 , 6, 38 | 2.9 | 5 |
| 40 | Middle cerebral artery infarction associated with sildenafil citrate (Viagra) use.. <i>Journal of Emergency Medicine Case Reports</i> , | 0.1 | 1 |
| 39 | Effects of sildenafil citrate on pancreatic and lung complications in an experimental L-arginine-induced acute pancreatitis model. <i>Przegląd Gastroenterologiczny</i> , 2021 , 16, 29-35 | 6 | 0 |
| 38 | Sildenafil 4.0-Integrated Synthetic Chemistry, Formulation and Analytical Strategies Effecting Immense Therapeutic and Societal Impact in the Fourth Industrial Era. <i>Pharmaceuticals</i> , 2021 , 14, | 5.2 | 5 |
| 37 | Sildenafil in ophthalmology: An update. <i>Survey of Ophthalmology</i> , 2021 , | 6.1 | 3 |
| 36 | The Weekend Drug; Recreational Use of Sildenafil Citrate and Concomitant Factors: A Cross-Sectional Study. <i>Frontiers in Medicine</i> , 2021 , 8, 665247 | 4.9 | 0 |
| 35 | Potential Cardiac Applications of Phosphodiesterase Type-5 Inhibition. 2004 , 207-237 | | 1 |
| 34 | Pathogenesis of Some Controversial Non-arteritic Anterior Ischemic Optic Neuropathy Clinical Entities. 2011 , 317-336 | | 1 |
| 33 | Sexual Dysfunction in Men and Women. 2011 , 778-816 | | 2 |
| 32 | [Phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension]. <i>Archivos De Cardiologia De Mexico</i> , 2015 , 85, 215-24 | 0.2 | 6 |
| 31 | Nitric oxide as a signaling molecule in the vascular system: an overview. <i>Journal of Cardiovascular Pharmacology</i> , 1999 , 34, 879-86 | 3.1 | 618 |

| | | |
|----|--|--------|
| 30 | Transient renal effects of sildenafil in male kidney transplant recipients. <i>Transplantation</i> , 2001 , 72, 1331-38 | 10 |
| 29 | Atrial fibrillation and continuous hypotension induced by sildenafil in an intermittent WPW syndrome patient. <i>International Heart Journal</i> , 1999 , 40, 827-30 | 16 |
| 28 | Fabrication and Characterization of Sildenafil Citrate Loaded Transfersomes as a Carrier for Transdermal Drug Delivery. <i>Pharmacy & Pharmacology International Journal</i> , 2017 , 5, | 0.7 6 |
| 27 | Role of cGMP and cAMP in the hemodynamic response to intrathecal sildenafil administration. <i>Clinics</i> , 2011 , 66, 1407-12 | 2.3 3 |
| 26 | Sexual function in hypertensive patients receiving treatment. <i>Vascular Health and Risk Management</i> , 2006 , 2, 447-55 | 4.4 31 |
| 25 | Therapeutic Potential of Phosphodiesterase Inhibitors for Endothelial Dysfunction- Related Diseases. <i>Current Pharmaceutical Design</i> , 2020 , 26, 3633-3651 | 3.3 3 |
| 24 | Subarachnoid Hemorrhage and Intracerebral Hematoma due to Sildenafil Ingestion in a Young Adult. <i>Journal of Korean Neurosurgical Society</i> , 2010 , 47, 210-2 | 2.3 11 |
| 23 | Nifedipine and Amlodipine Are Associated With Improved Mortality and Decreased Risk for Intubation and Mechanical Ventilation in Elderly Patients Hospitalized for COVID-19. <i>Cureus</i> , 2020 , 12, e8069 | 1.2 50 |
| 22 | Die Potenzierung der nitratinduzierten Hypotension durch Sildenafil ist unterschiedlich bei verschiedenen Nitraten. 2000 , 62-68 | |
| 21 | Herzkrankheiten und Sexualität Gefßrdung des kranken Herzens durch Sexualität oder Gefßrdung der Sexualität durch das kranke Herz. 2001 , 177-184 | |
| 20 | DIRECT EFFECTS OF SELECTIVE TYPE 5 PHOSPHODIESTERASE INHIBITORS ALONE OR WITH OTHER VASODILATORS ON THE ERECTILE RESPONSE IN CATS. <i>Journal of Urology</i> , 2001 , 1004-1009 | 2.5 |
| 19 | Hypogonadism, erectile dysfunction and infertility in men. 2002 , 147-200 | |
| 18 | Safety and Hemodynamic Effects of Sildenafil in Patients With Coronary Artery Disease. 2004 , 179-194 | |
| 17 | American College of Cardiology/American Heart Association Guidelines on the Use of Sildenafil in Patients With Cardiovascular Disease. 2004 , 271-277 | |
| 16 | Cardiovascular Safety of Sexual Activity and Phosphodiesterase Type 5 Inhibition. 2004 , 159-181 | |
| 15 | Sexual Activity As a Trigger of Myocardial Infarction/Ischemia. 2004 , 251-260 | |
| 14 | Phosphodiesterase Inhibitors. 2007 , 20-23 | |
| 13 | Treatment of Erectile Dysfunction in Chronic Kidney Disease. 2008 , 783-790 | |

12 Sexual Dysfunction in Patients With Neurological Disorders. **2008**, 651-672

11 Erectile Dysfunction. **2011**, 411-422

10 Tirotoksikoz nedenli erektil disfonksiyon izerine sildenafil etkisinin histopatolojik olarak deBerlendirilmesi. *Ege Tıp Dergisi*, 215-226 0

9 Spinal cord intramedullary hemorrhage (hematomyelia) after use of sildenafil: A very rare complication. *Journal of Surgery and Medicine*, 0.1

8 Cardiac Issues Related to Erectile Dysfunction. **2006**, 61-75

7 Four-year review of sildenafil citrate. *Reviews in Urology*, **2002**, 4 Suppl 3, S26-38 1 9

6 African traditional medicines for erectile dysfunction: elusive dream or imminent reality?. *Cardiovascular Journal of Africa*, **2007**, 18, 213-5 0.7 4

5 Effects of phosphodiesterase 5 inhibition on cardiovascular function in resistant hypertension: A systematic review.. *Life Sciences*, **2022**, 291, 120270 6.8

4 Prolonged oral sildenafil use-induced Mondor disease: a case report.

3 Sildenafil does not have a significant effect on the portal vein velocity, cross-sectional area, and congestion index in the dog. *Frontiers in Veterinary Science*, 9, 3.1

2 Sildenafil affects the human Kir2.1 and Kir2.2 channels at clinically relevant concentrations: Inhibition potentiated by low Ba²⁺. 14, 1

1 Multiple Cerebral Infarctions and Rhabdomyolysis After Sildenafil Citrate (Viagrafi) Intoxication: A Case Report. **2023**, 0